Wedbush Analysts Lower Earnings Estimates for Geron Co. (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Research analysts at Wedbush decreased their Q4 2025 earnings estimates for shares of Geron in a research report issued on Thursday, May 2nd. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will earn ($0.01) per share for the quarter, down from their previous forecast of $0.01. Wedbush has a “Outperform” rating and a $6.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.33) per share. Wedbush also issued estimates for Geron’s FY2028 earnings at $0.57 EPS.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The firm’s revenue for the quarter was down 77.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) EPS.

Several other analysts have also recently weighed in on GERN. The Goldman Sachs Group lifted their price target on Geron from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Friday, March 15th. TD Cowen started coverage on Geron in a report on Monday, April 29th. They set a “buy” rating and a $10.00 price target for the company. Robert W. Baird cut Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price target for the company. in a report on Tuesday, April 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $5.00 target price on shares of Geron in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Geron presently has an average rating of “Moderate Buy” and an average target price of $6.10.

Geron Stock Performance

NASDAQ:GERN opened at $3.87 on Monday. The stock has a market cap of $2.30 billion, a P/E ratio of -11.06 and a beta of 0.55. The stock has a 50 day simple moving average of $3.16 and a 200 day simple moving average of $2.41. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.03. Geron has a 1-year low of $1.64 and a 1-year high of $4.30.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Pathstone Family Office LLC bought a new stake in shares of Geron during the 3rd quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. boosted its position in Geron by 101.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 6,757 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Geron during the third quarter worth $29,000. SG Americas Securities LLC acquired a new position in shares of Geron during the third quarter worth $40,000. Finally, Twin Peaks Wealth Advisors LLC bought a new position in shares of Geron in the 4th quarter valued at $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.